The NVDA earnings have really set the tone for the market, and things are rocking today!

I didn’t have many bets going into today, but I am ready to start loading up again.

There continue to be many great small-cap “bottom bounces” and remarkably strong uptrends, which I want to participate in.

Today, I think we are on the edge of another breakout situation, and it is with a stock you are probably familiar with.  I talked about this stock a couple of weeks ago, and now is it trading over 30% higher.

If you follow the news trends and also look at this price chart, I think you’ll agree there is still a lot of potential ahead.

Bird Flu” is trending again in the news, as we just had the second report of it spreading to humans here in the US.

I expect this to be a very hot topic for a while, and that is going to keep a lot of attention on the small basket of stocks that have possible exposure there.

Pull up NanoViricides (NNVC) on your platform right now, and let’s dig into the details.

Let’s start with an article I came across yesterday on Bloomberg:

While the main stock traders are piling into is Moderna (MRNA), a stock I alerted my Bullseye Unlimited members to a few weeks ago on May 8th, when I started to see the Bird Flu searches skyrocketing, that stock is now way too overvalued, in my opinion.

NNVC on the other hand, is trading for only around $2 a share, and Yahoo reports a market cap under $30 million – even after the big move higher recently.

There aren’t many stocks in this space right now, and as the Bloomberg article reports, I think the handful that investors can connect to this trend will stay squarely on traders’ radars.

While we all know the scary story of the brewing pandemic – that currently doesn’t have a cure – NNVC recently announced that they have developed an antiviral drug that appears to be superior to the existing remedies, at least in early studies.

Read the whole announcement for yourself. It is incredible.

Pay particular attention to this line, “NanoViricides reports that in a lethal animal model of lung infection by Influenza A /H3N2 virus, NV-387 was found to have substantially superior antiviral effects compared to three approved anti-influenza drugs.

As you can imagine, the stock has been reacting very well since that announcement.

When I first brought this idea to your attention a couple of weeks ago, I asked, “What if NNVC is just getting started?”

That was when the Bird Flu stories were just getting attention, and NNVC was 30% lower than it is right now.

Well, look at how the stock has reacted since that first alert…

Since then, NNVC has hit a new 52-week high several times, and it is within a few cents of doing that again today.

That is quite simply one of the strongest trends in the whole market right now.

Unless there is a miracle cure for this disease, I think there will only be more traders finding this stock.

That is why it is important you carefully look at NNVC right now.

There has been a lot of news for NNVC lately. Make sure you are keeping up with all of it.  This is a fast-moving situation.

In fact, just moments ago, NNVC announced that it was bolstering a key partnership.

As you do your homework on NNVC, consider some of these points on the stock as well…

  • NanoViricides’ lead drug, NV-387, is in Phase 1 clinical trials.

  • Broad-spectrum antiviral NV-387 is showing promise against many virus families, including and beyond the Tripledemic (e.g., COVID-19, RSV, FLU).

  • No reported adverse events in Phase I SAD and MAD studies, even at the highest dose 40mg/Kg

  • Found to be non-immunogenic, non-mutagenic, non-allergenic, and non-phototoxic.

  • Strong safety allows use in pediatrics, adults with comorbidities, and immune-compromised patients, unlike the limitations of products currently in the market.

  • Developed Oral Syrup and Oral Gummies (soft solids) – good for geriatric and pediatric patients

  • Drugs are expected to continue to be effective even as the virus generates variants – unique receptor sites don’t change

  • The technology mimics unique receptor sites used by virus; delivers to specific targets using receptor-recognition (no bulky antibodies)

Spend time doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line:  While the stock might be a little stretched right now, it is impossible to know where a story like this will carry the price to.  NNVC is a fast-developing situation and it should be on the radar of every trader right now 📡.

I didn’t have time this morning to look deeply into the amount of shares shorted in this stock, but I imagine that could be a considerable driving force as well.

👉If someone has good data on that, can you reply to this email and let me know? (I’ll give you a shout-out next time I talk about NNVC.  Make sure you have a good source for your data!)

I hope you have a great trading day.  I’ll be watching NNVC all day long.

To Your Success,

Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull

*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received seventeen thousand dollars (cash) from Interactive Offers for advertising NanoViricides, Inc for a one day marketing program on May 23, 2024. We also previously received seventeen thousand dollars (cash) from Interactive Offers for advertising NanoViricides, Inc for a one day marketing program on may 8, 2024.  This amount was paid by someone else not connected to NanoViricides, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into NanoViricides, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear,

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.


Leave your comment

Skip to content